Another promising PI3Kδ isoform-specific PI3K inhibitor is IPI-145 (Infinity Pharmaceuticals) which has also demonstrated impressive results in patients with relapsed haematological cancers, including CLL and lymphoma [30]. Here, PIK3CB is linked to B-cell chronic lymphocytic leukemia.